Back to Clinical Trials

Brief Title: Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

INTRODUCTION

  • Org Study ID: NCI-2019-01266
  • Secondary ID: N/A
  • NCT ID: NCT03866382
  • Sponsor: National Cancer Institute (NCI)

BRIEF SUMMARY

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.

DETAILED DESCRIPTION

PRIMARY OBJECTIVE:

I. To evaluate the efficacy of cabozantinib s-malate (cabozantinib) combined with nivolumab and ipilimumab in the first or second-line (and beyond) setting for patients within each of the rare genitourinary (GU) variant histology group of interest, as measured by objective response rate (ORR).

SECONDARY OBJECTIVES:

I. To estimate the progression-free survival (PFS) for patients treated with cabozantinib combined with nivolumab and ipilimumab within each rare variant histology.

II. To estimate the overall survival (OS) for patients treated with cabozantinib combined with nivolumab and ipilimumab within each rare variant histology.

III. To estimate the clinical benefit rate (defined as complete response [CR] or partial response [PR] or stable disease [SD]) for patients treated with cabozantinib combined with nivolumab and ipilimumab within each rare variant histology.

IV. To assess the safety of treating patients with rare variant histologies with cabozantinib combined with nivolumab and ipilimumab.

V. To support tissue banking and collection of clinical follow-up data for GU tract rare histological variants.

EXPLORATORY OBJECTIVES:

I. To assess effects of treatment in patients with bone-only disease by bone scan.

OUTLINE:

Patients receive cabozantinib orally (PO), nivolumab intravenously (IV) and ipilimumab IV while on study. Patients undergo computed tomography (CT) scan, magnetic resonance imaging (MRI), positron emission tomography (PET) and bone scans throughout the study.

  • Overall Status
    Recruiting
  • Start Date
    May 13, 2019
  • Phase
    Phase 2
  • Study Type
    Interventional

PRIMARY OUTCOMES

Primary Outcome 1 - Measure:

Primary Outcome 1 - Timeframe: N/A

CONDITION

  • Bladder Adenocarcinoma
  • Bladder Clear Cell Adenocarcinoma
  • Bladder Mixed Adenocarcinoma
  • Bladder Neuroendocrine Carcinoma
  • Bladder Small Cell Neuroendocrine Carcinoma
  • Bladder Squamous Cell Carcinoma
  • Chromophobe Renal Cell Carcinoma
  • Collecting Duct Carcinoma
  • Invasive Bladder Giant Cell Urothelial Carcinoma
  • Invasive Bladder Lymphoepithelioma-Like Carcinoma
  • Invasive Bladder Nested Urothelial Carcinoma
  • Invasive Bladder Plasmacytoid Urothelial Carcinoma
  • Invasive Bladder Sarcomatoid Urothelial Carcinoma
  • Invasive Bladder Urothelial Carcinoma
  • Kidney Medullary Carcinoma
  • Large Cell Neuroendocrine Carcinoma
  • Malignant Testicular Leydig Cell Tumor
  • Malignant Testicular Sertoli Cell Tumor
  • Metastatic Bladder Carcinoma
  • Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma
  • Metastatic Bladder Giant Cell Urothelial Carcinoma
  • Metastatic Bladder Large Cell Neuroendocrine Carcinoma
  • Metastatic Bladder Lipid-Rich Urothelial Carcinoma
  • Metastatic Bladder Micropapillary Urothelial Carcinoma
  • Metastatic Bladder Plasmacytoid Urothelial Carcinoma
  • Metastatic Bladder Sarcomatoid Urothelial Carcinoma
  • Metastatic Bladder Small Cell Neuroendocrine Carcinoma
  • Metastatic Bladder Squamous Cell Carcinoma
  • Metastatic Chromophobe Renal Cell Carcinoma
  • Metastatic Kidney Medullary Carcinoma
  • Metastatic Malignant Genitourinary System Neoplasm
  • Metastatic Papillary Renal Cell Carcinoma
  • Metastatic Penile Carcinoma
  • Metastatic Prostate Small Cell Neuroendocrine Carcinoma
  • Metastatic Sarcomatoid Renal Cell Carcinoma
  • Metastatic Urethral Carcinoma
  • Papillary Renal Cell Carcinoma
  • Sarcomatoid Renal Cell Carcinoma
  • Stage IV Bladder Cancer AJCC v8
  • Stage IV Penile Cancer AJCC v8
  • Stage IV Renal Cell Cancer AJCC v8
  • Stage IV Urethral Cancer AJCC v8
  • Stage IVB Prostate Cancer AJCC v8
  • Urachal Adenocarcinoma
  • Urethral Clear Cell Adenocarcinoma

ELIGIBILITY

Inclusion Criteria:
* Metastatic disease defined as new or progressive lesions on cross-sectional imaging or bone scan. Patients must have at least:
* One measurable site of disease as per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1

- * One bone lesion on bone scan (tec99 or sodium fluoride [NaF] PET/CT, CT or MRI) for the bone-only cohort.

- * Histologically confirmed diagnosis of one of the following metastatic cohorts:
* Small cell/ neuroendocrine carcinoma of the bladder- All urothelial carcinomas with any amount of neuroendocrine differentiation (including small cell differentiation) will be included. If the tumor is purely neuroendocrine, metastasis from another site of origin should be clinically excluded

- * Adenocarcinoma of the bladder, or urachal adenocarcinoma, or bladder/urethra clear cell adenocarcinoma - must be pure (per World Health Organization [WHO] definition), (i.e. urothelial carcinoma with glandular differentiation is not considered a pure adenocarcinoma

- * Squamous cell carcinoma of the bladder - must be pure (i.e. urothelial carcinoma with squamous differentiation is not considered a pure squamous cell carcinoma)

- * Plasmacytoid urothelial carcinoma - Tumor should show predominantly > or equal ~ 50% plasmacytoid histology (including all types of discohesive growth, such as tumors with signet-ring and/or rhabdoid features as well)

- * Any penile cancer

- * Sarcomatoid renal cell carcinoma - Tumor should be predominantly sarcomatoid ~ 50% (including rhabdoid differentiation) is also unclassified renal cell carcinomas (RCCs): all (assuming they are high grade with metastasis) malignant angiomyolipomas are allowed

- * Sarcomatoid urothelial carcinoma - Tumor should show predominantly ~ 50% sarcomatoid differentiation

- * Renal medullary carcinoma - Per WHO definition, ideally confirmed with immunostains

- * Renal collecting duct carcinoma - Per WHO definition (medullary involvement, predominant tubular morphology, desmoplastic stromal reaction, high grade cytology, infiltrative growth pattern, and absence of other renal cell carcinoma subtype or urothelial carcinoma)

- * Bone only urothelial carcinoma or other non-prostate GU tumor

- * Urethra carcinoma- May be of any histology but if urothelial carcinoma then must be isolated to the urethra and not have metachronous or synchronous urothelial carcinoma of the bladder

- * Other miscellaneous histologic variants of the urothelial carcinoma, such as, but not limited to : micropapillary (Tumor should show predominantly > or equal 50% micropapillary architecture), giant cell, lipid-rich, clear cell and nested variants (Tumor should predominantly > or equal 50% show these features), large cell neuroendocrine carcinoma, lymphoepithelioma-like carcinoma and mixed patterns will be considered, as well as small cell neuroendocrine prostate cancer (Only treatment-naïve primary small cell of prostate with any amount of small cell component allowed. Post-treatment small cell prostatic carcinomas are not allowed), Malignant testicular Sertoli or Leydig cell tumors, and papillary and chromophobe RCC
* Note: Translocation positive renal cell carcinoma patients are eligible. However, AREN1721 should be considered before this trial

- * Hematoxylin and eosin (H&E) slides from diagnostic tumor tissue for retrospective central pathology review

- * Patients may have received up to 2 systemic anti-cancer treatments or be treatment naive. Patients with small cell carcinoma should have received a platinum-based combination regimen either as neoadjuvant, adjuvant or first-line treatment). Patients in the bone-only cohort may be urothelial carcinoma histology but must receive standard cisplatin-based chemotherapy (if cisplatin-eligible)

- * Age >= 18 years

- * Patients must be able to swallow oral formulation of the tablets

- * Karnofsky performance status >= 80%

- * Absolute neutrophil count (ANC) >= 1,000/mcL

- * Platelet count >= 75,000/mcL

- * Total bilirubin =< 1.5 x upper limit of normal (ULN). For subjects with known Gilbert's disease or similar syndrome with slow conjugation of bilirubin, total bilirubin =< 3.0 mg/dL - * Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3.0 x institutional upper limit of normal (ULN) (or =< 5 x ULN for patients with liver metastases or Gilbert's disease) - * Creatinine =< 1.5 x upper limit of normal (ULN) OR creatinine clearance >= 40 mL/min/1.73 m^2 (calculated using the Chronic Kidney Disease Epidemiology [CKD-EPI] equation or Cockcroft-Gault formula) for patients with creatinine levels above institutional normal

- * Hemoglobin >= 9 g/dL (transfusion of packed red blood cells [PRBCs] allowed)

- * Serum albumin >= 3.2 g/dL

- * Lipase and amylase =< 2.0 x ULN and no radiologic (on baseline anatomical imaging) or clinical evidence of pancreatitis - * Prior treatment with MET or VEGFR inhibitors is allowed. However, prior cabozantinib will not be allowed. Also, patients that have received both prior MET or VEGF and prior PD-1/PD-L1/CTLA-4 (sequentially or in combination) are also not allowed - * Prior treatment with any therapy on the PD-1/PD-L1 axis or anti- CTLA-4/CTLA-4 inhibitors is allowed, either in the perioperative or in the metastatic setting. However, patients that have received both prior MET or VEGF and prior PD-1/PD-L1/CTLA-4 (sequentially or in combination) are not allowed - * Human immunodeficiency virus (HIV)-positive patients are eligible if on stable dose of highly active antiretroviral therapy (HAART), no clinically significant drug-drug interactions are anticipated with the current HAART regimen, CD4 counts are greater than 350 and viral load is undetectable - * Patients with rheumatoid arthritis and other rheumatologic arthropathies, Sjogren's syndrome and psoriasis controlled with topical medication only and patients with positive serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies etc. are eligible but should be considered for rheumatologic evaluation for the presence of target organ involvement and potential need for systemic treatment - * Patients with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones or medications (e.g. thyroiditis managed with propylthiouracil [PTU] or methimazole) including physiologic oral corticosteroids are eligible - * Patients who have evidence of active or acute diverticulitis, intra-abdominal abscess, and gastrointestinal (GI) obstruction, within 12 months are not eligible - * Women of childbearing potential must have a negative pregnancy test =< 7 days prior to registration
* Women of childbearing potential include women who have experienced menarche and who have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are not postmenopausal. Post menopause is defined as amenorrhea >= 12 consecutive months. Note: women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antiestrogens, ovarian suppression or any other reversible reason

- * Pregnant women may not participate in this study because with cabozantinib, nivolumab, and ipilimumab have potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with cabozantinib, nivolumab, and ipilimumab, breastfeeding should be discontinued if the mother is treated with these agents

- * The patient has received no cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (e.g., cytokines or antibodies) within 2 weeks before the first dose of study treatment

- * The patient has received no radiation therapy:
* To the lungs and mediastinum or abdomen within 4 weeks before the first dose of study treatment, or has ongoing complications, or is healing from prior radiation therapy

- * To brain metastasis within 3 weeks for whole-brain radiotherapy (WBXRT), and 2 weeks for stereotactic body radiation therapy (SBRT) before the first dose of study treatment

- * To the abdomen within 4 weeks before the first dose of study treatment, or has ongoing complications, or is healing from prior radiation therapy

- * To any other site(s) within 2 weeks before the first dose of study treatment

- * The patient has received no radionuclide treatment within 6 weeks of the first dose of study treatment

- * The patient has received no prior treatment with a small molecule kinase inhibitor within 14 days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment

- * The patient has received no prior treatment with hormonal therapy within 14 days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment. Subjects receiving gonadotropin-releasing hormone (GnRH) agonists and antagonists are allowed to participate

- * The patient has not received any other type of investigational agent within 14 days before the first dose of study treatment

- * The patient must have recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade 1 from toxicity due to all prior therapies except alopecia, neuropathy and other non-clinically significant adverse events (AEs) defined as lab elevation with no associated symptoms or sequelae - * The patient may not have active brain metastases or epidural disease. Patients with brain metastases previously treated with whole brain radiation or radiosurgery who are asymptomatic and do not require steroid treatment for at least 2 weeks before starting study treatment are eligible. Neurosurgical resection of brain metastases or brain biopsy is permitted if completed at least 3 months before starting study treatment. Baseline brain imaging with contrast-enhanced CT or MRI scans for subjects with known brain metastases is required to confirm eligibility - * No concomitant treatment with warfarin. Aspirin (up to 325 mg/day), thrombin or factor Xa inhibitors, low-dose warfarin (=< 1 mg/day), prophylactic and therapeutic low molecular weight heparin (LMWH) are permitted - * No chronic concomitant treatment with strong CYP3A4 inducers (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, and St. John's wort) or strong CYP3A4 inhibitors
* Because the lists of these agents are constantly changing, it is important to regularly consult medical reference texts such as the Physicians' Desk Reference may also provide this information. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product

- * The patient has not experienced any of the following:
* Clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment

- * Hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood per day within 1 months before the first dose of study treatment

- * Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment

- * The patient has no tumor invading any major blood vessels

- * The patient has no evidence of tumor invading the GI tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinib. Patients with rectal tumor masses are not eligible

- * The patient has no uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:
* Cardiovascular disorders including:
* Congestive heart failure (CHF): New York Heart Association (NYHA) class III (moderate) or class IV (severe) at the time of screening.

- * Concurrent uncontrolled hypertension defined as sustained blood pressure (BP) > 150 mm Hg systolic, or > 90 mm Hg diastolic despite optimal antihypertensive treatment within 7 days of the first dose of study treatment

- * The subject has a corrected QT interval calculated by the Fridericia formula (QTcF) > 500 ms within 28 days before randomization. Note: if initial QTcF is found to be > 500 ms, two additional electrocardiograms (EKGs) separated by at least 3 minutes should be performed. If the average of these three consecutive results for QTcF is =< 500 ms, the subject meets eligibility in this regard - * Any history of congenital long QT syndrome - * Any of the following within 6 months before registration of study treatment:
* Unstable angina pectoris

- * Clinically-significant cardiac arrhythmias (patients with atrial fibrillation are eligible)

- * Stroke (including transient ischemic attack [TIA], or other ischemic event)

- * Myocardial infarction

- * Cardiomyopathy

- * No significant gastrointestinal disorders particularly those associated with a high risk of perforation or fistula formation including:
* Any of the following that have not resolved within 28 days before the first dose of study treatment:
* Active peptic ulcer disease

- * Acute diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, or malabsorption syndrome

- * None of the following within 2 years before the first dose of study treatment:
* Abdominal fistula or genitourinary fistula

- * Gastrointestinal perforation

- * Bowel obstruction or gastric outlet obstruction

- * Intra-abdominal abscess. Note: Complete resolution of an intra-abdominal abscess must be confirmed prior to initiating treatment with cabozantinib even if the abscess occurred more than 2 years before the first dose of study treatment

- * Disorders associated with a high risk of fistula formation including percutaneous endoscopic gastrostomy (PEG) tube placement are not eligible

- * No other clinically significant disorders such as:
* Severe active infection requiring IV systemic treatment within 14 days before the first dose of study treatment

- * Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment

- * History of organ or allogeneic stem cell transplant

- * Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment (for asymptomatic patients with an elevated thyroid-stimulating hormone [TSH], thyroid replacement may be initiated if clinically indicated without delaying the start of study treatment)

- * No history of major surgery as follows:
* Major surgery within 3 months of the first dose of cabozantinib; however, if there were no wound healing complications, patients with rapidly growing aggressive cancers, may start as soon as 6 weeks if wound has completely healed post-surgery

- * Minor surgery within 1 month of the first dose of cabozantinib if there were no wound healing complications or within 3 months of the first dose of cabozantinib if there were wound complications excluding core biopsies and mediport placement

- * Complete wound healing from prior surgery must be confirmed before the first dose of cabozantinib irrespective of the time from surgery

- * No history of severe hypersensitivity reaction to any monoclonal antibody

- * No evidence of active malignancy, requiring systemic treatment within 2 years of registration

- * No history of allergic reactions attributed to compounds of similar chemical or biologic composition to cabozantinib, nivolumab, ipilimumab or other agents used in study

- * No positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection. If HBV sAG is positive, subsequent ribonucleic acid (RNA) polymerase chain reaction (PCR) must be negative

- * No patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids. These include, but are not limited to patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome should be excluded because of the risk of recurrence or exacerbation of disease

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: Andrea B Apolo

Role: Principal Investigator

Affiliation: Alliance for Clinical Trials in Oncology

Overall Contact

Name: N/A

Phone: N/A

Email: N/A

LOCATION

Facility Status Contact
Facility: University of Alabama at Birmingham Cancer Center
Birmingham, Alabama 35233
United States
Status: Recruiting Contact: Contact
Site Public Contact
205-934-0220
tmyrick@uab.edu

Principal Investigator
Arnab Basu

Facility: Mayo Clinic in Arizona
Scottsdale, Arizona 85259
United States
Status: Recruiting Contact: Contact
Site Public Contact
855-776-0015

Principal Investigator
Lance C. Pagliaro

Facility: Community Cancer Institute
Clovis, California 93611
United States
Status: Recruiting Contact: Contact
Site Public Contact
559-387-1827

Principal Investigator
Uzair B. Chaudhary

Facility: Epic Care-Dublin
Dublin, California 94568
United States
Status: Recruiting Contact: Contact
Site Public Contact
925-875-1677

Principal Investigator
Lisa Bailey

Facility: Epic Care Partners in Cancer Care
Emeryville, California 94608
United States
Status: Recruiting Contact: Contact
Site Public Contact
510-629-6682

Principal Investigator
Lisa Bailey

Facility: Los Angeles General Medical Center
Los Angeles, California 90033
United States
Status: Recruiting Contact: Contact
Site Public Contact
323-865-0451
uscnorrisinfo@med.usc.edu

Principal Investigator
Anishka D'Souza

Facility: USC / Norris Comprehensive Cancer Center
Los Angeles, California 90033
United States
Status: Recruiting Contact: Contact
Site Public Contact
323-865-0451

Principal Investigator
Anishka D'Souza

Facility: Contra Costa Regional Medical Center
Martinez, California 94553-3156
United States
Status: Recruiting Contact: Contact
Site Public Contact
925-957-5400

Principal Investigator
Lisa Bailey

Facility: USC Norris Oncology/Hematology-Newport Beach
Newport Beach, California 92663
United States
Status: Recruiting Contact: Contact
Site Public Contact
323-865-0451

Principal Investigator
Anishka D'Souza

Facility: Epic Care Cyberknife Center
Walnut Creek, California 94597
United States
Status: Recruiting Contact: Contact
Site Public Contact
510-465-8016
somega@bati.org

Principal Investigator
Lisa Bailey

Facility: MedStar Georgetown University Hospital
Washington, District of Columbia 20007
United States
Status: Recruiting Contact: Contact
Site Public Contact
202-444-2223

Principal Investigator
Nancy A. Dawson

Facility: Holy Cross Hospital
Fort Lauderdale, Florida 33308
United States
Status: Recruiting Contact: Contact
Site Public Contact
954-267-7748

Principal Investigator
Tareq Al Baghdadi

Facility: Orlando Health Cancer Institute
Orlando, Florida 32806
United States
Status: Recruiting Contact: Contact
Site Public Contact
321-841-7246
CancerClinicalTrials@orlandohealth.com

Principal Investigator
Hatem Hassanein

Facility: Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia 30322
United States
Status: Recruiting Contact: Contact
Site Public Contact
404-778-1868

Principal Investigator
Mehmet A. Bilen

Facility: Kootenai Health - Coeur d'Alene
Coeur d'Alene, Idaho 83814
United States
Status: Recruiting Contact: Contact
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Principal Investigator
John M. Schallenkamp

Facility: Kootenai Clinic Cancer Services - Post Falls
Post Falls, Idaho 83854
United States
Status: Recruiting Contact: Contact
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Principal Investigator
John M. Schallenkamp

Facility: Kootenai Cancer Clinic
Sandpoint, Idaho 83864
United States
Status: Recruiting Contact: Contact
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Principal Investigator
John M. Schallenkamp

Facility: Northwestern University
Chicago, Illinois 60611
United States
Status: Recruiting Contact: Contact
Site Public Contact
312-695-1301
cancer@northwestern.edu

Principal Investigator
Jeffrey A. Sosman

Facility: Rush University Medical Center
Chicago, Illinois 60612
United States
Status: Recruiting Contact: Contact
Site Public Contact
312-942-5498
clinical_trials@rush.edu

Principal Investigator
Thomas C. Westbrook

Facility: University of Chicago Comprehensive Cancer Center
Chicago, Illinois 60637
United States
Status: Recruiting Contact: Contact
Site Public Contact
773-702-8222
cancerclinicaltrials@bsd.uchicago.edu

Principal Investigator
Walter M. Stadler

Facility: Carle at The Riverfront
Danville, Illinois 61832
United States
Status: Recruiting Contact: Contact
Site Public Contact
800-446-5532
Research@Carle.com

Principal Investigator
Vamsi K. Vasireddy

Facility: Cancer Care Specialists of Illinois - Decatur
Decatur, Illinois 62526
United States
Status: Recruiting Contact: Contact
Site Public Contact
217-876-4762
morganthaler.jodi@mhsil.com

Principal Investigator
Bryan A. Faller

Facility: Carle Physician Group-Effingham
Effingham, Illinois 62401
United States
Status: Recruiting Contact: Contact
Site Public Contact
800-446-5532
Research@carle.com

Principal Investigator
Vamsi K. Vasireddy

Facility: Crossroads Cancer Center
Effingham, Illinois 62401
United States
Status: Recruiting Contact: Contact
Site Public Contact
217-876-4762
morganthaler.jodi@mhsil.com

Principal Investigator
Bryan A. Faller

Facility: Carle Physician Group-Mattoon/Charleston
Mattoon, Illinois 61938
United States
Status: Recruiting Contact: Contact
Site Public Contact
800-446-5532
Research@carle.com

Principal Investigator
Vamsi K. Vasireddy

Facility: Loyola University Medical Center
Maywood, Illinois 60153
United States
Status: Recruiting Contact: Contact
Site Public Contact
708-226-4357

Principal Investigator
Ami Badami

Facility: UC Comprehensive Cancer Center at Silver Cross
New Lenox, Illinois 60451
United States
Status: Recruiting Contact: Contact
Site Public Contact
773-702-8222
cancerclinicaltrials@bsd.uchicago.edu

Principal Investigator
Walter M. Stadler

Facility: Cancer Care Center of O'Fallon
O'Fallon, Illinois 62269
United States
Status: Recruiting Contact: Contact
Site Public Contact
217-876-4762
morganthaler.jodi@mhsil.com

Principal Investigator
Bryan A. Faller

Facility: University of Chicago Medicine-Orland Park
Orland Park, Illinois 60462
United States
Status: Recruiting Contact: Contact
Site Public Contact
773-702-8222
cancerclinicaltrials@bsd.uchicago.edu

Principal Investigator
Walter M. Stadler

Facility: Southern Illinois University School of Medicine
Springfield, Illinois 62702
United States
Status: Recruiting Contact: Contact
Site Public Contact
217-545-7929

Principal Investigator
Bryan A. Faller

Facility: Springfield Clinic
Springfield, Illinois 62702
United States
Status: Recruiting Contact: Contact
Site Public Contact
800-444-7541

Principal Investigator
Bryan A. Faller

Facility: Memorial Medical Center
Springfield, Illinois 62781
United States
Status: Recruiting Contact: Contact
Site Public Contact
217-528-7541
pallante.beth@mhsil.com

Principal Investigator
Bryan A. Faller

Facility: Carle Cancer Center
Urbana, Illinois 61801
United States
Status: Recruiting Contact: Contact
Site Public Contact
800-446-5532
Research@carle.com

Principal Investigator
Vamsi K. Vasireddy

Facility: Reid Health
Richmond, Indiana 47374
United States
Status: Recruiting Contact: Contact
Site Public Contact
937-528-2900
clinical.trials@daytonncorp.org

Principal Investigator
Howard M. Gross

Facility: Mary Greeley Medical Center
Ames, Iowa 50010
United States
Status: Recruiting Contact: Contact
Site Public Contact
515-956-4132

Principal Investigator
Joseph J. Merchant

Facility: McFarland Clinic - Ames
Ames, Iowa 50010
United States
Status: Recruiting Contact: Contact
Site Public Contact
515-239-4734
ksoder@mcfarlandclinic.com

Principal Investigator
Joseph J. Merchant

Facility: McFarland Clinic - Boone
Boone, Iowa 50036
United States
Status: Recruiting Contact: Contact
Site Public Contact
515-956-4132

Principal Investigator
Joseph J. Merchant

Facility: McFarland Clinic - Trinity Cancer Center
Fort Dodge, Iowa 50501
United States
Status: Recruiting Contact: Contact
Site Public Contact
515-956-4132

Principal Investigator
Joseph J. Merchant

Facility: McFarland Clinic - Jefferson
Jefferson, Iowa 50129
United States
Status: Recruiting Contact: Contact
Site Public Contact
515-956-4132

Principal Investigator
Joseph J. Merchant

Facility: McFarland Clinic - Marshalltown
Marshalltown, Iowa 50158
United States
Status: Recruiting Contact: Contact
Site Public Contact
515-956-4132

Principal Investigator
Joseph J. Merchant

Facility: HaysMed University of Kansas Health System
Hays, Kansas 67601
United States
Status: Recruiting Contact: Contact
Site Public Contact
785-623-5774

Principal Investigator
Elizabeth M. Wulff-Burchfield

Facility: Lawrence Memorial Hospital
Lawrence, Kansas 66044
United States
Status: Recruiting Contact: Contact
Site Public Contact
785-505-2800
Stephanie.Norris@LMH.ORG

Principal Investigator
Elizabeth M. Wulff-Burchfield

Facility: Olathe Health Cancer Center
Olathe, Kansas 66061
United States
Status: Recruiting Contact: Contact
Site Public Contact
913-355-8000
Jeni.wakefield@olathehealth.org

Principal Investigator
Elizabeth M. Wulff-Burchfield

Facility: Ascension Via Christi - Pittsburg
Pittsburg, Kansas 66762
United States
Status: Recruiting Contact: Contact
Site Public Contact
620-235-7900
jennifer.jameson@ascension.org

Principal Investigator
Elizabeth M. Wulff-Burchfield

Facility: Freeman Physician Group of Pittsburg
Pittsburg, Kansas 66762
United States
Status: Recruiting Contact: Contact
Site Public Contact
BNMathew@freemanhealth.com

Principal Investigator
Elizabeth M. Wulff-Burchfield

Facility: Salina Regional Health Center
Salina, Kansas 67401
United States
Status: Recruiting Contact: Contact
Site Public Contact
785-452-7038
mleepers@srhc.com

Principal Investigator
Elizabeth M. Wulff-Burchfield

Facility: University of Kansas Health System Saint Francis Campus
Topeka, Kansas 66606
United States
Status: Recruiting Contact: Contact
Site Public Contact
785-295-8000

Principal Investigator
Elizabeth M. Wulff-Burchfield

Facility: University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas 66205
United States
Status: Recruiting Contact: Contact
Site Public Contact
913-588-3671
KUCC_Navigation@kumc.edu

Principal Investigator
Elizabeth M. Wulff-Burchfield

Facility: University of Kentucky/Markey Cancer Center
Lexington, Kentucky 40536
United States
Status: Recruiting Contact: Contact
Site Public Contact
859-257-3379

Principal Investigator
Zin W. Myint

Facility: Greater Baltimore Medical Center
Baltimore, Maryland 21204
United States
Status: Recruiting Contact: Contact
Site Public Contact
443-849-3706

Principal Investigator
Ari H. Elman

Facility: National Institutes of Health Clinical Center
Bethesda, Maryland 20892
United States
Status: Recruiting Contact: Contact
Site Public Contact
800-411-1222

Principal Investigator
Andrea B. Apolo

Facility: Lahey Hospital and Medical Center
Burlington, Massachusetts 01805
United States
Status: Recruiting Contact: Contact
Site Public Contact
781-744-3421
lhmc-cancer-clinical-trials@lahey.org

Principal Investigator
Brendan Connell

Facility: Lahey Medical Center-Peabody
Peabody, Massachusetts 01960
United States
Status: Recruiting Contact: Contact
Site Public Contact
781-744-3421
lhmc-cancer-clinical-trials@lahey.org

Principal Investigator
Brendan Connell

Facility: Winchester Hospital
Winchester, Massachusetts 01890
United States
Status: Recruiting Contact: Contact
Site Public Contact
888-823-5923
ctsucontact@westat.com

Principal Investigator
Brendan Connell

Facility: Saint Joseph Mercy Hospital
Ann Arbor, Michigan 48106
United States
Status: Recruiting Contact: Contact
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Principal Investigator
Tareq Al Baghdadi

Facility: Saint Joseph Mercy Brighton
Brighton, Michigan 48114
United States
Status: Recruiting Contact: Contact
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Principal Investigator
Tareq Al Baghdadi

Facility: Trinity Health IHA Medical Group Hematology Oncology - Brighton
Brighton, Michigan 48114
United States
Status: Recruiting Contact: Contact
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Principal Investigator
Tareq Al Baghdadi

Facility: Saint Joseph Mercy Canton
Canton, Michigan 48188
United States
Status: Recruiting Contact: Contact
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Principal Investigator
Tareq Al Baghdadi

Facility: Trinity Health IHA Medical Group Hematology Oncology - Canton
Canton, Michigan 48188
United States
Status: Recruiting Contact: Contact
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Principal Investigator
Tareq Al Baghdadi

Facility: Saint Joseph Mercy Chelsea
Chelsea, Michigan 48118
United States
Status: Recruiting Contact: Contact
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Principal Investigator
Tareq Al Baghdadi

Facility: Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Chelsea, Michigan 48118
United States
Status: Recruiting Contact: Contact
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Principal Investigator
Tareq Al Baghdadi

Facility: Hematology Oncology Consultants-Clarkston
Clarkston, Michigan 48346
United States
Status: Recruiting Contact: Contact
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Principal Investigator
Tareq Al Baghdadi

Facility: Newland Medical Associates-Clarkston
Clarkston, Michigan 48346
United States
Status: Recruiting Contact: Contact
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Principal Investigator
Tareq Al Baghdadi

Facility: Henry Ford Macomb Hospital-Clinton Township
Clinton Township, Michigan 48038
United States
Status: Recruiting Contact: Contact
Site Public Contact
313-916-3721
CTOResearch@hfhs.org

Principal Investigator
Haythem Y. Ali

Facility: Henry Ford Hospital
Detroit, Michigan 48202
United States
Status: Recruiting Contact: Contact
Site Public Contact
313-916-3721
CTOResearch@hfhs.org

Principal Investigator
Haythem Y. Ali

Facility: Ascension Saint John Hospital
Detroit, Michigan 48236
United States
Status: Recruiting Contact: Contact
Site Public Contact
313-343-3166
karen.forman@ascension.org

Principal Investigator
Tareq Al Baghdadi

Facility: Great Lakes Cancer Management Specialists-Doctors Park
East China Township, Michigan 48054
United States
Status: Recruiting Contact: Contact
Site Public Contact
313-343-3166
karen.forman@ascension.org

Principal Investigator
Tareq Al Baghdadi

Facility: Genesee Cancer and Blood Disease Treatment Center
Flint, Michigan 48503
United States
Status: Recruiting Contact: Contact
Site Public Contact
810-762-8038
wstrong@ghci.org

Principal Investigator
Tareq Al Baghdadi

Facility: Genesee Hematology Oncology PC
Flint, Michigan 48503
United States
Status: Recruiting Contact: Contact
Site Public Contact
810-762-8038
wstrong@ghci.org

Principal Investigator
Tareq Al Baghdadi

Facility: Genesys Hurley Cancer Institute
Flint, Michigan 48503
United States
Status: Recruiting Contact: Contact
Site Public Contact
810-762-8038
wstrong@ghci.org

Principal Investigator
Tareq Al Baghdadi

Facility: Hurley Medical Center
Flint, Michigan 48503
United States
Status: Recruiting Contact: Contact
Site Public Contact
810-762-8038
wstrong@ghci.org

Principal Investigator
Tareq Al Baghdadi

Facility: Academic Hematology Oncology Specialists
Grosse Pointe Woods, Michigan 48236
United States
Status: Recruiting Contact: Contact
Site Public Contact
313-343-3166
karen.forman@ascension.org

Principal Investigator
Tareq Al Baghdadi

Facility: Great Lakes Cancer Management Specialists-Van Elslander Cancer Center
Grosse Pointe Woods, Michigan 48236
United States
Status: Recruiting Contact: Contact
Site Public Contact
313-343-3166
karen.forman@ascension.org

Principal Investigator
Tareq Al Baghdadi

Facility: University of Michigan Health - Sparrow Lansing
Lansing, Michigan 48912
United States
Status: Recruiting Contact: Contact
Site Public Contact
517-364-3712
harsha.trivedi@umhsparrow.org

Principal Investigator
Tareq Al Baghdadi

Facility: Trinity Health Saint Mary Mercy Livonia Hospital
Livonia, Michigan 48154
United States
Status: Recruiting Contact: Contact
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Principal Investigator
Tareq Al Baghdadi

Facility: Great Lakes Cancer Management Specialists-Macomb Medical Campus
Macomb, Michigan 48044
United States
Status: Recruiting Contact: Contact
Site Public Contact
313-343-3166
karen.forman@ascension.org

Principal Investigator
Tareq Al Baghdadi

Facility: 21st Century Oncology-Pontiac
Pontiac, Michigan 48341
United States
Status: Recruiting Contact: Contact
Site Public Contact
248-858-6215
Emily.Crofts@trinity-health.org

Principal Investigator
Tareq Al Baghdadi

Facility: Newland Medical Associates-Pontiac
Pontiac, Michigan 48341
United States
Status: Recruiting Contact: Contact
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Principal Investigator
Tareq Al Baghdadi

Facility: Saint Joseph Mercy Oakland
Pontiac, Michigan 48341
United States
Status: Recruiting Contact: Contact
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Principal Investigator
Tareq Al Baghdadi

Facility: Ascension Saint Mary's Hospital
Saginaw, Michigan 48601
United States
Status: Recruiting Contact: Contact
Site Public Contact
989-907-8411
lori.srebinski@ascension.org

Principal Investigator
Tareq Al Baghdadi

Facility: Oncology Hematology Associates of Saginaw Valley PC
Saginaw, Michigan 48604
United States
Status: Recruiting Contact: Contact
Site Public Contact
989-907-8411
lori.srebinski@ascension.org

Principal Investigator
Tareq Al Baghdadi

Facility: Bhadresh Nayak MD PC-Sterling Heights
Sterling Heights, Michigan 48312
United States
Status: Recruiting Contact: Contact
Site Public Contact
313-343-3166
karen.forman@ascension.org

Principal Investigator
Tareq Al Baghdadi

Facility: Ascension Saint Joseph Hospital
Tawas City, Michigan 48764
United States
Status: Recruiting Contact: Contact
Site Public Contact
989-907-8411
lori.srebinski@ascension.org

Principal Investigator
Tareq Al Baghdadi

Facility: Great Lakes Cancer Management Specialists-Macomb Professional Building
Warren, Michigan 48093
United States
Status: Recruiting Contact: Contact
Site Public Contact
313-343-3166
karen.forman@ascension.org

Principal Investigator
Tareq Al Baghdadi

Facility: Saint John Macomb-Oakland Hospital
Warren, Michigan 48093
United States
Status: Recruiting Contact: Contact
Site Public Contact
313-343-3166
karen.forman@ascension.org

Principal Investigator
Tareq Al Baghdadi

Facility: Saint Mary's Oncology/Hematology Associates of West Branch
West Branch, Michigan 48661
United States
Status: Recruiting Contact: Contact
Site Public Contact
989-907-8411
lori.srebinski@ascension.org

Principal Investigator
Tareq Al Baghdadi

Facility: Huron Gastroenterology PC
Ypsilanti, Michigan 48106
United States
Status: Recruiting Contact: Contact
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Principal Investigator
Tareq Al Baghdadi

Facility: Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
Ypsilanti, Michigan 48197
United States
Status: Recruiting Contact: Contact
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Principal Investigator
Tareq Al Baghdadi

Facility: Essentia Health - Deer River Clinic
Deer River, Minnesota 56636
United States
Status: Recruiting Contact: Contact
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

Principal Investigator
Bret E. Friday

Facility: Essentia Health Cancer Center
Duluth, Minnesota 55805
United States
Status: Recruiting Contact: Contact
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

Principal Investigator
Bret E. Friday

Facility: Essentia Health Hibbing Clinic
Hibbing, Minnesota 55746
United States
Status: Recruiting Contact: Contact
Site Public Contact
218-786-3308

Principal Investigator
Bret E. Friday

Facility: Mayo Clinic in Rochester
Rochester, Minnesota 55905
United States
Status: Recruiting Contact: Contact
Site Public Contact
855-776-0015

Principal Investigator
Lance C. Pagliaro

Facility: Regions Hospital
Saint Paul, Minnesota 55101
United States
Status: Recruiting Contact: Contact
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

Principal Investigator
Daniel M. Anderson

Facility: Essentia Health Sandstone
Sandstone, Minnesota 55072
United States
Status: Recruiting Contact: Contact
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

Principal Investigator
Bret E. Friday

Facility: Lakeview Hospital
Stillwater, Minnesota 55082
United States
Status: Recruiting Contact: Contact
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

Principal Investigator
Daniel M. Anderson

Facility: Essentia Health Virginia Clinic
Virginia, Minnesota 55792
United States
Status: Recruiting Contact: Contact
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

Principal Investigator
Bret E. Friday

Facility: Ridgeview Medical Center
Waconia, Minnesota 55387
United States
Status: Recruiting Contact: Contact
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

Principal Investigator
Daniel M. Anderson

Facility: University of Mississippi Medical Center
Jackson, Mississippi 39216
United States
Status: Recruiting Contact: Contact
Site Public Contact
601-815-6700

Principal Investigator
John C. Henegan

Facility: Saint Francis Medical Center
Cape Girardeau, Missouri 63703
United States
Status: Recruiting Contact: Contact
Site Public Contact
573-334-2230
sfmc@sfmc.net

Principal Investigator
Bryan A. Faller

Facility: Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri 63141
United States
Status: Recruiting Contact: Contact
Site Public Contact
800-600-3606
info@siteman.wustl.edu

Principal Investigator
Joel Picus

Facility: Parkland Health Center - Farmington
Farmington, Missouri 63640
United States
Status: Recruiting Contact: Contact
Site Public Contact
314-996-5569

Principal Investigator
Bryan A. Faller

Facility: Truman Medical Centers
Kansas City, Missouri 64108
United States
Status: Recruiting Contact: Contact
Site Public Contact
816-404-4375

Principal Investigator
Elizabeth M. Wulff-Burchfield

Facility: University of Kansas Cancer Center - Lee's Summit
Lee's Summit, Missouri 64064
United States
Status: Recruiting Contact: Contact
Site Public Contact
913-588-3671
KUCC_Navigation@kumc.edu

Principal Investigator
Elizabeth M. Wulff-Burchfield

Facility: Washington University School of Medicine
Saint Louis, Missouri 63110
United States
Status: Recruiting Contact: Contact
Site Public Contact
800-600-3606
info@siteman.wustl.edu

Principal Investigator
Joel Picus

Facility: Mercy Hospital South
Saint Louis, Missouri 63128
United States
Status: Recruiting Contact: Contact
Site Public Contact
314-525-6042
Danielle.Werle@mercy.net

Principal Investigator
Jay W. Carlson

Facility: Siteman Cancer Center-South County
Saint Louis, Missouri 63129
United States
Status: Recruiting Contact: Contact
Site Public Contact
800-600-3606
info@siteman.wustl.edu

Principal Investigator
Joel Picus

Facility: Missouri Baptist Medical Center
Saint Louis, Missouri 63131
United States
Status: Recruiting Contact: Contact
Site Public Contact
314-996-5569

Principal Investigator
Bryan A. Faller

Facility: Siteman Cancer Center at Christian Hospital
Saint Louis, Missouri 63136
United States
Status: Recruiting Contact: Contact
Site Public Contact
800-600-3606
info@siteman.wustl.edu

Principal Investigator
Joel Picus

Facility: Mercy Hospital Saint Louis
Saint Louis, Missouri 63141
United States
Status: Recruiting Contact: Contact
Site Public Contact
314-251-7066

Principal Investigator
Jay W. Carlson

Facility: Siteman Cancer Center at Saint Peters Hospital
Saint Peters, Missouri 63376
United States
Status: Recruiting Contact: Contact
Site Public Contact
800-600-3606
info@siteman.wustl.edu

Principal Investigator
Joel Picus

Facility: Sainte Genevieve County Memorial Hospital
Sainte Genevieve, Missouri 63670
United States
Status: Recruiting Contact: Contact
Site Public Contact
314-996-5569

Principal Investigator
Bryan A. Faller

Facility: Missouri Baptist Sullivan Hospital
Sullivan, Missouri 63080
United States
Status: Recruiting Contact: Contact
Site Public Contact
314-996-5569

Principal Investigator
Bryan A. Faller

Facility: BJC Outpatient Center at Sunset Hills
Sunset Hills, Missouri 63127
United States
Status: Recruiting Contact: Contact
Site Public Contact
314-996-5569

Principal Investigator
Bryan A. Faller

Facility: Community Hospital of Anaconda
Anaconda, Montana 59711
United States
Status: Recruiting Contact: Contact
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Principal Investigator
John M. Schallenkamp

Facility: Billings Clinic Cancer Center
Billings, Montana 59101
United States
Status: Recruiting Contact: Contact
Site Public Contact
800-996-2663
research@billingsclinic.org

Principal Investigator
John M. Schallenkamp

Facility: Bozeman Deaconess Hospital
Bozeman, Montana 59715
United States
Status: Recruiting Contact: Contact
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Principal Investigator
John M. Schallenkamp

Facility: Benefis Healthcare- Sletten Cancer Institute
Great Falls, Montana 59405
United States
Status: Recruiting Contact: Contact
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Principal Investigator
John M. Schallenkamp

Facility: Kalispell Regional Medical Center
Kalispell, Montana 59901
United States
Status: Recruiting Contact: Contact
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Principal Investigator
John M. Schallenkamp

Facility: Community Medical Hospital
Missoula, Montana 59804
United States
Status: Recruiting Contact: Contact
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Principal Investigator
John M. Schallenkamp

Facility: Nebraska Medicine-Bellevue
Bellevue, Nebraska 68123
United States
Status: Recruiting Contact: Contact
Site Public Contact
402-559-6941
unmcrsa@unmc.edu

Principal Investigator
Benjamin A. Teply

Facility: Nebraska Cancer Specialists/Oncology Hematology West PC - MECC
Omaha, Nebraska 68114
United States
Status: Recruiting Contact: Contact
Site Public Contact
402-334-4773

Principal Investigator
Ralph J. Hauke

Facility: Nebraska Methodist Hospital
Omaha, Nebraska 68114
United States
Status: Recruiting Contact: Contact
Site Public Contact
402-354-5144

Principal Investigator
Ralph J. Hauke

Facility: Oncology Associates PC
Omaha, Nebraska 68114
United States
Status: Recruiting Contact: Contact
Site Public Contact
402-354-5860
info@oa-oc.com

Principal Investigator
Ralph J. Hauke

Facility: Nebraska Medicine-Village Pointe
Omaha, Nebraska 68118
United States
Status: Recruiting Contact: Contact
Site Public Contact
402-559-5600

Principal Investigator
Benjamin A. Teply

Facility: University of Nebraska Medical Center
Omaha, Nebraska 68198
United States
Status: Recruiting Contact: Contact
Site Public Contact
402-559-6941
unmcrsa@unmc.edu

Principal Investigator
Benjamin A. Teply

Facility: OptumCare Cancer Care at Charleston
Las Vegas, Nevada 89102
United States
Status: Recruiting Contact: Contact
Site Public Contact
702-384-0013
research@sncrf.org

Principal Investigator
John A. Ellerton

Facility: OptumCare Cancer Care at Fort Apache
Las Vegas, Nevada 89148
United States
Status: Recruiting Contact: Contact
Site Public Contact
702-384-0013
research@sncrf.org

Principal Investigator
John A. Ellerton

Facility: Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey 07920
United States
Status: Recruiting Contact: Contact
Site Public Contact
212-639-7592

Principal Investigator
Samuel A. Funt

Facility: Memorial Sloan Kettering Monmouth
Middletown, New Jersey 07748
United States
Status: Recruiting Contact: Contact
Site Public Contact
212-639-7592

Principal Investigator
Samuel A. Funt

Facility: Memorial Sloan Kettering Bergen
Montvale, New Jersey 07645
United States
Status: Recruiting Contact: Contact
Site Public Contact
212-639-7592

Principal Investigator
Samuel A. Funt

Facility: Maimonides Medical Center
Brooklyn, New York 11219
United States
Status: Recruiting Contact: Contact
Site Public Contact
718-765-2500

Principal Investigator
Kevin Becker

Facility: Memorial Sloan Kettering Commack
Commack, New York 11725
United States
Status: Recruiting Contact: Contact
Site Public Contact
212-639-7592

Principal Investigator
Samuel A. Funt

Facility: Memorial Sloan Kettering Westchester
Harrison, New York 10604
United States
Status: Recruiting Contact: Contact
Site Public Contact
212-639-7592

Principal Investigator
Samuel A. Funt

Facility: Northwell Health/Center for Advanced Medicine
Lake Success, New York 11042
United States
Status: Recruiting Contact: Contact
Site Public Contact
516-734-8896

Principal Investigator
Thomas P. Bradley

Facility: NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, New York 10032
United States
Status: Recruiting Contact: Contact
Site Public Contact
212-342-5162
cancerclinicaltrials@cumc.columbia.edu

Principal Investigator
Mark N. Stein

Facility: Memorial Sloan Kettering Cancer Center
New York, New York 10065
United States
Status: Recruiting Contact: Contact
Site Public Contact
212-639-7592

Principal Investigator
Samuel A. Funt

Facility: NYP/Weill Cornell Medical Center
New York, New York 10065
United States
Status: Recruiting Contact: Contact
Site Public Contact
212-746-1848

Principal Investigator
Cora N. Sternberg

Facility: University of Rochester
Rochester, New York 14642
United States
Status: Recruiting Contact: Contact
Site Public Contact
585-275-5830

Principal Investigator
Paul M. Barr

Facility: State University of New York Upstate Medical University
Syracuse, New York 13210
United States
Status: Recruiting Contact: Contact
Site Public Contact
315-464-5476

Principal Investigator
Alina Basnet

Facility: Memorial Sloan Kettering Nassau
Uniondale, New York 11553
United States
Status: Recruiting Contact: Contact
Site Public Contact
212-639-7592

Principal Investigator
Samuel A. Funt

Facility: UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina 27599
United States
Status: Recruiting Contact: Contact
Site Public Contact
877-668-0683
cancerclinicaltrials@med.unc.edu

Principal Investigator
Tracy L. Rose

Facility: Margaret R Pardee Memorial Hospital
Hendersonville, North Carolina 28791
United States
Status: Recruiting Contact: Contact
Site Public Contact
828-696-4716
pardeecancerresearch@unchealth.unc.edu

Principal Investigator
Praveen Vashist

Facility: Strecker Cancer Center-Belpre
Belpre, Ohio 45714
United States
Status: Recruiting Contact: Contact
Site Public Contact
800-523-3977
sheree@columbusccop.org

Principal Investigator
Timothy D. Moore

Facility: Dayton Physicians LLC-Miami Valley South
Centerville, Ohio 45459
United States
Status: Recruiting Contact: Contact
Site Public Contact
937-528-2900
clinical.trials@daytonncorp.org

Principal Investigator
Howard M. Gross

Facility: Adena Regional Medical Center
Chillicothe, Ohio 45601
United States
Status: Recruiting Contact: Contact
Site Public Contact
877-779-7585
sheree@columbusccop.org

Principal Investigator
Timothy D. Moore

Facility: Ohio State University Comprehensive Cancer Center
Columbus, Ohio 43210
United States
Status: Recruiting Contact: Contact
Site Public Contact
800-293-5066
Jamesline@osumc.edu

Principal Investigator
Amir Mortazavi

Facility: Mount Carmel East Hospital
Columbus, Ohio 43213
United States
Status: Recruiting Contact: Contact
Site Public Contact
614-488-2118
sheree@columbusccop.org

Principal Investigator
Timothy D. Moore

Facility: Columbus Oncology and Hematology Associates Inc
Columbus, Ohio 43214
United States
Status: Recruiting Contact: Contact
Site Public Contact
614-788-3860
Jennifer.Sexton@ohiohealth.com

Principal Investigator
Shakir Sarwar

Facility: Riverside Methodist Hospital
Columbus, Ohio 43214
United States
Status: Recruiting Contact: Contact
Site Public Contact
614-788-3860
Jennifer.Sexton@ohiohealth.com

Principal Investigator
Shakir Sarwar

Facility: Grant Medical Center
Columbus, Ohio 43215
United States
Status: Recruiting Contact: Contact
Site Public Contact
614-788-3860
Jennifer.Sexton@ohiohealth.com

Principal Investigator
Shakir Sarwar

Facility: The Mark H Zangmeister Center
Columbus, Ohio 43219
United States
Status: Recruiting Contact: Contact
Site Public Contact
614-488-2118
sheree@columbusccop.org

Principal Investigator
Timothy D. Moore

Facility: Mount Carmel Health Center West
Columbus, Ohio 43222
United States
Status: Recruiting Contact: Contact
Site Public Contact
614-234-5433
sheree@columbusccop.org

Principal Investigator
Timothy D. Moore

Facility: Doctors Hospital
Columbus, Ohio 43228
United States
Status: Recruiting Contact: Contact
Site Public Contact
614-788-3860
Jennifer.Sexton@ohiohealth.com

Principal Investigator
Shakir Sarwar

Facility: Dayton Physician LLC-Miami Valley Hospital North
Dayton, Ohio 45415
United States
Status: Recruiting Contact: Contact
Site Public Contact
937-528-2900
clinical.trials@daytonncorp.org

Principal Investigator
Howard M. Gross

Facility: Delaware Health Center-Grady Cancer Center
Delaware, Ohio 43015
United States
Status: Recruiting Contact: Contact
Site Public Contact
614-788-3860
Jennifer.Sexton@ohiohealth.com

Principal Investigator
Shakir Sarwar

Facility: Grady Memorial Hospital
Delaware, Ohio 43015
United States
Status: Recruiting Contact: Contact
Site Public Contact
614-788-3860
Jennifer.Sexton@ohiohealth.com

Principal Investigator
Shakir Sarwar

Facility: Armes Family Cancer Center
Findlay, Ohio 45840
United States
Status: Recruiting Contact: Contact
Site Public Contact
937-528-2900
clinical.trials@daytonncorp.org

Principal Investigator
Howard M. Gross

Facility: Dayton Physicians LLC-Atrium
Franklin, Ohio 45005
United States
Status: Recruiting Contact: Contact
Site Public Contact
937-528-2900
clinical.trials@daytonncorp.org

Principal Investigator
Howard M. Gross

Facility: Greater Dayton Cancer Center
Kettering, Ohio 45409
United States
Status: Recruiting Contact: Contact
Site Public Contact
937-528-2900
clinical.trials@daytonncorp.org

Principal Investigator
Howard M. Gross

Facility: Kettering Medical Center
Kettering, Ohio 45429
United States
Status: Recruiting Contact: Contact
Site Public Contact
937-528-2900
clinical.trials@daytonncorp.org

Principal Investigator
Howard M. Gross

Facility: Fairfield Medical Center
Lancaster, Ohio 43130
United States
Status: Recruiting Contact: Contact
Site Public Contact
740-687-8863
sheree@columbusccop.org

Principal Investigator
Timothy D. Moore

Facility: OhioHealth Mansfield Hospital
Mansfield, Ohio 44903
United States
Status: Recruiting Contact: Contact
Site Public Contact
614-788-3860
Jennifer.Sexton@ohiohealth.com

Principal Investigator
Shakir Sarwar

Facility: Marietta Memorial Hospital
Marietta, Ohio 45750
United States
Status: Recruiting Contact: Contact
Site Public Contact
800-523-3977
sheree@columbusccop.org

Principal Investigator
Timothy D. Moore

Facility: OhioHealth Marion General Hospital
Marion, Ohio 43302
United States
Status: Recruiting Contact: Contact
Site Public Contact
614-788-3860
Jennifer.Sexton@ohiohealth.com

Principal Investigator
Shakir Sarwar

Facility: Memorial Hospital
Marysville, Ohio 43040
United States
Status: Recruiting Contact: Contact
Site Public Contact
614-488-2118
sheree@columbusccop.org

Principal Investigator
Timothy D. Moore

Facility: Knox Community Hospital
Mount Vernon, Ohio 43050
United States
Status: Recruiting Contact: Contact
Site Public Contact
740-393-9000
sheree@columbusccop.org

Principal Investigator
Timothy D. Moore

Facility: Licking Memorial Hospital
Newark, Ohio 43055
United States
Status: Recruiting Contact: Contact
Site Public Contact
740-348-4000
sheree@columbusccop.org

Principal Investigator
Timothy D. Moore

Facility: Southern Ohio Medical Center
Portsmouth, Ohio 45662
United States
Status: Recruiting Contact: Contact
Site Public Contact
614-488-2118
sheree@columbusccop.org

Principal Investigator
Timothy D. Moore

Facility: Springfield Regional Cancer Center
Springfield, Ohio 45504
United States
Status: Recruiting Contact: Contact
Site Public Contact
937-528-2900
clinical.trials@daytonncorp.org

Principal Investigator
Timothy D. Moore

Facility: Saint Ann's Hospital
Westerville, Ohio 43081
United States
Status: Recruiting Contact: Contact
Site Public Contact
614-234-5433
sheree@columbusccop.org

Principal Investigator
Timothy D. Moore

Facility: Genesis Healthcare System Cancer Care Center
Zanesville, Ohio 43701
United States
Status: Recruiting Contact: Contact
Site Public Contact
740-454-5232
sheree@columbusccop.org

Principal Investigator
Timothy D. Moore

Facility: Cancer Centers of Southwest Oklahoma Research
Lawton, Oklahoma 73505
United States
Status: Recruiting Contact: Contact
Site Public Contact
877-231-4440

Principal Investigator
Adanma Anji Ayanambakkam Attanathi

Facility: University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma 73104
United States
Status: Recruiting Contact: Contact
Site Public Contact
405-271-8777
ou-clinical-trials@ouhsc.edu

Principal Investigator
Adanma Anji Ayanambakkam Attanathi

Facility: Oklahoma Cancer Specialists and Research Institute-Tulsa
Tulsa, Oklahoma 74146
United States
Status: Recruiting Contact: Contact
Site Public Contact
918-505-3200

Principal Investigator
Adanma Anji Ayanambakkam Attanathi

Facility: Providence Newberg Medical Center
Newberg, Oregon 97132
United States
Status: Recruiting Contact: Contact
Site Public Contact
503-215-2614
CanRsrchStudies@providence.org

Principal Investigator
Alison K. Conlin

Facility: Providence Willamette Falls Medical Center
Oregon City, Oregon 97045
United States
Status: Recruiting Contact: Contact
Site Public Contact
503-215-2614
CanRsrchStudies@providence.org

Principal Investigator
Alison K. Conlin

Facility: Providence Portland Medical Center
Portland, Oregon 97213
United States
Status: Recruiting Contact: Contact
Site Public Contact
503-215-2614
CanRsrchStudies@providence.org

Principal Investigator
Alison K. Conlin

Facility: Providence Saint Vincent Medical Center
Portland, Oregon 97225
United States
Status: Recruiting Contact: Contact
Site Public Contact
503-215-2614
CanRsrchStudies@providence.org

Principal Investigator
Alison K. Conlin

Facility: Oregon Health and Science University
Portland, Oregon 97239
United States
Status: Recruiting Contact: Contact
Site Public Contact
503-494-1080
trials@ohsu.edu

Principal Investigator
Christopher W. Ryan

Facility: Lehigh Valley Hospital-Cedar Crest
Allentown, Pennsylvania 18103
United States
Status: Recruiting Contact: Contact
Site Public Contact
610-402-9543
Morgan_M.Horton@lvhn.org

Principal Investigator
Tareq Al Baghdadi

Facility: Lehigh Valley Hospital - Muhlenberg
Bethlehem, Pennsylvania 18017
United States
Status: Recruiting Contact: Contact
Site Public Contact
610-402-9543
Morgan_M.Horton@lvhn.org

Principal Investigator
Tareq Al Baghdadi

Facility: UPMC Hillman Cancer Center Erie
Erie, Pennsylvania 16505
United States
Status: Recruiting Contact: Contact
Site Public Contact
412-389-5208
haneydl@upmc.edu

Principal Investigator
Leonard J. Appleman

Facility: UPMC Cancer Centers - Arnold Palmer Pavilion
Greensburg, Pennsylvania 15601
United States
Status: Recruiting Contact: Contact
Site Public Contact
724-838-1900

Principal Investigator
Leonard J. Appleman

Facility: UPMC Hillman Cancer Center - Monroeville
Monroeville, Pennsylvania 15146
United States
Status: Recruiting Contact: Contact
Site Public Contact
412-389-5208
haneydl@upmc.edu

Principal Investigator
Leonard J. Appleman

Facility: Arnold Palmer Cancer Center Medical Oncology Norwin
N. Huntingdon, Pennsylvania 15642
United States
Status: Recruiting Contact: Contact
Site Public Contact
412-389-5208
haneydl@upmc.edu

Principal Investigator
Leonard J. Appleman

Facility: University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania 15232
United States
Status: Recruiting Contact: Contact
Site Public Contact
412-647-8073

Principal Investigator
Leonard J. Appleman

Facility: UPMC-Passavant Hospital
Pittsburgh, Pennsylvania 15237
United States
Status: Recruiting Contact: Contact
Site Public Contact
412-367-6454

Principal Investigator
Leonard J. Appleman

Facility: UPMC-Saint Clair Hospital Cancer Center
Pittsburgh, Pennsylvania 15243
United States
Status: Recruiting Contact: Contact
Site Public Contact
412-502-3920

Principal Investigator
Leonard J. Appleman

Facility: University Cancer Specialists - Alcoa
Alcoa, Tennessee 37701
United States
Status: Recruiting Contact: Contact
Site Public Contact
865-305-5120
bherbert@utmck.edu

Principal Investigator
Saikrishna Gadde

Facility: University of Tennessee - Knoxville
Knoxville, Tennessee 37920
United States
Status: Recruiting Contact: Contact
Site Public Contact
865-544-9773

Principal Investigator
Saikrishna Gadde

Facility: Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee 37232
United States
Status: Recruiting Contact: Contact
Site Public Contact
800-811-8480

Principal Investigator
Brian I. Rini

Facility: UT Southwestern Simmons Cancer Center - RedBird
Dallas, Texas 75237
United States
Status: Recruiting Contact: Contact
Site Public Contact
214-648-7097
canceranswerline@utsouthwestern.edu

Principal Investigator
Suzanne M. Cole

Facility: UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas 75390
United States
Status: Recruiting Contact: Contact
Site Public Contact
214-648-7097
canceranswerline@UTSouthwestern.edu

Principal Investigator
Suzanne M. Cole

Facility: UT Southwestern/Simmons Cancer Center-Fort Worth
Fort Worth, Texas 76104
United States
Status: Recruiting Contact: Contact
Site Public Contact
214-648-7097
canceranswerline@UTSouthwestern.edu

Principal Investigator
Suzanne M. Cole

Facility: UT Southwestern Clinical Center at Richardson/Plano
Richardson, Texas 75080
United States
Status: Recruiting Contact: Contact
Site Public Contact
972-669-7044
Suzanne.cole@utsouthwestern.edu

Principal Investigator
Suzanne M. Cole

Facility: Harrison HealthPartners Hematology and Oncology-Bremerton
Bremerton, Washington 98310
United States
Status: Recruiting Contact: Contact
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

Principal Investigator
Richard L. Deming

Facility: Kadlec Clinic Hematology and Oncology
Kennewick, Washington 99336
United States
Status: Recruiting Contact: Contact
Site Public Contact
509-783-4637
research@kadlecmed.org

Principal Investigator
Alison K. Conlin

Facility: Valley Medical Center
Renton, Washington 98055
United States
Status: Recruiting Contact: Contact
Site Public Contact
425-228-3440
research@valleymed.org

Principal Investigator
John A. Ellerton

Facility: PeaceHealth Southwest Medical Center
Vancouver, Washington 98664
United States
Status: Recruiting Contact: Contact
Site Public Contact
360-514-3940
kmakin-bond@peacehealth.org

Principal Investigator
Alison K. Conlin

Facility: Duluth Clinic Ashland
Ashland, Wisconsin 54806
United States
Status: Recruiting Contact: Contact
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

Principal Investigator
Bret E. Friday

Facility: Aurora Cancer Care-Southern Lakes VLCC
Burlington, Wisconsin 53105
United States
Status: Recruiting Contact: Contact
Site Public Contact
414-302-2304
ncorp@aurora.org

Principal Investigator
Thomas J. Saphner

Facility: Marshfield Medical Center-EC Cancer Center
Eau Claire, Wisconsin 54701
United States
Status: Recruiting Contact: Contact
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

Principal Investigator
Michael Husak

Facility: Mayo Clinic Health System-Eau Claire Clinic
Eau Claire, Wisconsin 54701
United States
Status: Recruiting Contact: Contact
Site Public Contact
855-776-0015

Principal Investigator
Lance C. Pagliaro

Facility: Aurora Health Care Germantown Health Center
Germantown, Wisconsin 53022
United States
Status: Recruiting Contact: Contact
Site Public Contact
414-302-2304
ncorp@aurora.org

Principal Investigator
Thomas J. Saphner

Facility: Aurora Cancer Care-Grafton
Grafton, Wisconsin 53024
United States
Status: Recruiting Contact: Contact
Site Public Contact
414-302-2304
ncorp@aurora.org

Principal Investigator
Thomas J. Saphner

Facility: Aurora BayCare Medical Center
Green Bay, Wisconsin 54311
United States
Status: Recruiting Contact: Contact
Site Public Contact
414-302-2304
ncorp@aurora.org

Principal Investigator
Thomas J. Saphner

Facility: Aurora Cancer Care-Kenosha South
Kenosha, Wisconsin 53142
United States
Status: Recruiting Contact: Contact
Site Public Contact
414-302-2304
ncorp@aurora.org

Principal Investigator
Thomas J. Saphner

Facility: Aurora Bay Area Medical Group-Marinette
Marinette, Wisconsin 54143
United States
Status: Recruiting Contact: Contact
Site Public Contact
414-302-2304
ncorp@aurora.org

Principal Investigator
Thomas J. Saphner

Facility: Marshfield Medical Center-Marshfield
Marshfield, Wisconsin 54449
United States
Status: Recruiting Contact: Contact
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

Principal Investigator
Michael Husak

Facility: Aurora Cancer Care-Milwaukee
Milwaukee, Wisconsin 53209
United States
Status: Recruiting Contact: Contact
Site Public Contact
414-302-2304
ncorp@aurora.org

Principal Investigator
Thomas J. Saphner

Facility: Aurora Saint Luke's Medical Center
Milwaukee, Wisconsin 53215
United States
Status: Recruiting Contact: Contact
Site Public Contact
414-302-2304
ncorp@aurora.org

Principal Investigator
Thomas J. Saphner

Facility: Aurora Sinai Medical Center
Milwaukee, Wisconsin 53233
United States
Status: Recruiting Contact: Contact
Site Public Contact
414-302-2304
ncorp@aurora.org

Principal Investigator
Thomas J. Saphner

Facility: Marshfield Clinic-Minocqua Center
Minocqua, Wisconsin 54548
United States
Status: Recruiting Contact: Contact
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

Principal Investigator
Michael Husak

Facility: ProHealth D N Greenwald Center
Mukwonago, Wisconsin 53149
United States
Status: Recruiting Contact: Contact
Site Public Contact
research.institute@phci.org

Principal Investigator
Timothy R. Wassenaar

Facility: ProHealth Oconomowoc Memorial Hospital
Oconomowoc, Wisconsin 53066
United States
Status: Recruiting Contact: Contact
Site Public Contact
262-928-7878

Principal Investigator
Timothy R. Wassenaar

Facility: Vince Lombardi Cancer Clinic - Oshkosh
Oshkosh, Wisconsin 54904
United States
Status: Recruiting Contact: Contact
Site Public Contact
414-302-2304
ncorp@aurora.org

Principal Investigator
Thomas J. Saphner

Facility: Aurora Cancer Care-Racine
Racine, Wisconsin 53406
United States
Status: Recruiting Contact: Contact
Site Public Contact
414-302-2304
ncorp@aurora.org

Principal Investigator
Thomas J. Saphner

Facility: Marshfield Medical Center-Rice Lake
Rice Lake, Wisconsin 54868
United States
Status: Recruiting Contact: Contact
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

Principal Investigator
Michael Husak

Facility: Vince Lombardi Cancer Clinic-Sheboygan
Sheboygan, Wisconsin 53081
United States
Status: Recruiting Contact: Contact
Site Public Contact
414-302-2304
ncorp@aurora.org

Principal Investigator
Thomas J. Saphner

Facility: Marshfield Medical Center-River Region at Stevens Point
Stevens Point, Wisconsin 54482
United States
Status: Recruiting Contact: Contact
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

Principal Investigator
Michael Husak

Facility: Aurora Medical Center in Summit
Summit, Wisconsin 53066
United States
Status: Recruiting Contact: Contact
Site Public Contact
414-302-2304
ncorp@aurora.org

Principal Investigator
Thomas J. Saphner

Facility: Vince Lombardi Cancer Clinic-Two Rivers
Two Rivers, Wisconsin 54241
United States
Status: Recruiting Contact: Contact
Site Public Contact
414-302-2304
ncorp@aurora.org

Principal Investigator
Thomas J. Saphner

Facility: ProHealth Waukesha Memorial Hospital
Waukesha, Wisconsin 53188
United States
Status: Recruiting Contact: Contact
Site Public Contact
262-928-7632

Principal Investigator
Timothy R. Wassenaar

Facility: UW Cancer Center at ProHealth Care
Waukesha, Wisconsin 53188
United States
Status: Recruiting Contact: Contact
Site Public Contact
262-928-5539
Chanda.miller@phci.org

Principal Investigator
Timothy R. Wassenaar

Facility: Aurora Cancer Care-Milwaukee West
Wauwatosa, Wisconsin 53226
United States
Status: Recruiting Contact: Contact
Site Public Contact
414-302-2304
ncorp@aurora.org

Principal Investigator
Thomas J. Saphner

Facility: Aurora West Allis Medical Center
West Allis, Wisconsin 53227
United States
Status: Recruiting Contact: Contact
Site Public Contact
414-302-2304
ncorp@aurora.org

Principal Investigator
Thomas J. Saphner

Facility: Marshfield Medical Center - Weston
Weston, Wisconsin 54476
United States
Status: Recruiting Contact: Contact
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

Principal Investigator
Michael Husak